Beximco, Beacon pharma make Japanese Covid-19 drug
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Saturday
July 02, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SATURDAY, JULY 02, 2022
Beximco, Beacon pharma make Japanese Covid-19 drug

Health

TBS Report
04 April, 2020, 08:45 pm
Last modified: 05 April, 2020, 11:09 am

Related News

  • Asia's factories feeble despite China bounce, feeds global recession fears
  • North Korea blames 'alien things' near border with South for Covid outbreak
  • S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Easing Covid-19 rules, growth focus aid China bulls' cautious return
  • 'We did not face an extreme crisis with Omicron. But this wave is spreading faster'

Beximco, Beacon pharma make Japanese Covid-19 drug

Beacon pharmaceuticals will hand over the drug to the Directorate General of Drug Administration on Sunday

TBS Report
04 April, 2020, 08:45 pm
Last modified: 05 April, 2020, 11:09 am
File Photo: Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. Reuters/Issei Kato
File Photo: Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. Reuters/Issei Kato

Two local drug makers — Beacon and Beximco pharmaceuticals — have produced Favipiravir, an antiviral drug that is being used by some countries to treat the Covid-19 patients.

They will give the medicine to the government and the hospitals where coronavirus patients are being treated instead of selling it to the pharmacies.

"It took us just one month to make the drug. We are excited," Mohammad Ebadul Karim, managing director of Beacon Pharma, told The Business Standard.

Beacon will hand over the drug to the Directorate General of Drug Administration on Sunday.

But making the drug was not that easy as there was no confirmed data and raw materials, Karim said.

In the first batch, Beacon has produced Favipiravir for 100 patients only and the company is on the way to boost production by this month. 

Beximco Pharmaceuticals will give the medicine directly to the hospitals where Covid-19 patients are being treated, said Rabbur Reza, chief operating officer of the company.

"We have made drug on fast track and informed the government and hospitals about it," Reza said.

Though the price has been set at Tk400 a tablet, he said they would give it for free.

As there is no confirmed drug for Covid-19 patients, different countries are using different types of influenza antiviral drugs.  

For example, Japan and China have used Favipiravir, marketed as Avigan by Fujifilm Toyama in Japan. Also, Turkey has recently used it. 

Reza said commonly used molecules for Covid-19 were lopinavir/ritonavir, favipiravir, oseltamivir, remdesivir, chloroquine, Hydroxychloroquine (HCQ) etc. HCQ and chloroquine and Azithromycin combination became popular due a relatively large trial in Europe and Trump's bold statement on this combination.

"Covid-19 has different phases – mild, moderate and serious. There is no harm in giving the drug at the mild stage," he said.

Favipiravir is a patented drug in Japan, but Bangladesh as a least developed country can make and market the medicine till 2033.

The US Food and Drug Administration has not specifically approved any medication for treating Covid-19. World Health Organization, UK National Health Service and Australian health authorities have not provided any advice on the use of Favipiravir. 

Bangladesh / Coronavirus chronicle / Top News / Covid-19 in Bangladesh

Coronavirus / COVID-19 / Favipiravir / medicine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • In rain, heat, filth – they fight against cancer
    In rain, heat, filth – they fight against cancer
  • Tejgaon Industrial Area has become an illegal parking lot for all kinds of vehicles, from buses to trucks to rickshaws. Photo: Mumit M
    Rickshaw garages and truck stands: How Tejgaon Industrial Area turned into a mess
  • TBS Illustration
    Universities may launch online classes again after Eid

MOST VIEWED

  • In rain, heat, filth – they fight against cancer
    In rain, heat, filth – they fight against cancer
  • Photo: Collected
    ISR authorised to conduct clinical trial of SARS-CoV-2 vaccine in Bangladesh
  • Photo: Collected
    Daily Covid deaths rise to 5
  •  A Rohingya camp in Cox’s Bazar, Bangladesh, November 16, 2018. Photo: Reuters/Mohammad Ponir Hossain
    Dengue cases on rise in Rohingya camps
  • Representational image
    Drug use by the youths may affect economy: Speakers
  • Daily Covid deaths rise to 4 with 2,183 new cases
    Daily Covid deaths rise to 4 with 2,183 new cases

Related News

  • Asia's factories feeble despite China bounce, feeds global recession fears
  • North Korea blames 'alien things' near border with South for Covid outbreak
  • S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Easing Covid-19 rules, growth focus aid China bulls' cautious return
  • 'We did not face an extreme crisis with Omicron. But this wave is spreading faster'

Features

The eye-catching commuter: Suzuki Gixxer SF 155

The eye-catching commuter: Suzuki Gixxer SF 155

47m | Wheels
Photo: Collected

Sapiens – A Graphic History 

22h | Book Review
Black-naped Monarch male  Photo: Enam Ul Haque

Black-naped Monarch: A sovereign who never abandoned the Indian subcontinent

23h | Panorama
The 136-year-old company on its last legs

The 136-year-old company on its last legs

1d | Features

More Videos from TBS

Dhaka University celebrating 102nd founding anniversary today

Dhaka University celebrating 102nd founding anniversary today

22h | Videos
Ctg Int'l Trade Fair returns after a 2-year hiatus without Covid restrictions

Ctg Int'l Trade Fair returns after a 2-year hiatus without Covid restrictions

22h | Videos
Bangladeshis among top 6 nationalities seeking asylum in Europe

Bangladeshis among top 6 nationalities seeking asylum in Europe

23h | Videos
RUET organises Robotronics 2.0

RUET organises Robotronics 2.0

23h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

4
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

5
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

6
Investor Hiru fined Tk2cr for market manipulation
Stocks

Investor Hiru fined Tk2cr for market manipulation

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
The Dazzling Fake Flowers: Is there any alternative to artificial flowers while decorating homes, showrooms, offices and business establishments? Fresh flowers are undoubtedly beautiful, but they dry out quickly. Hence, the demand for plastic flowers is rising day by day. Traders said these lifelike silk flowers usually come from China and Thailand. The photo was taken from the 29th International Trade Fair of the Chattogram Chamber on Friday. PHOTO: Mohammad Minhaj Uddin

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net